1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Sweden >
  5. Cellectis Acquires Cellartis AB

M&A Deal Summary

Cellectis Acquires Cellartis AB

On November 4, 2011, Cellectis acquired life science company Cellartis AB

Acquisition Highlights
  • This is Cellectis’ 1st transaction in the Life Science sector.
  • This is Cellectis’ 1st transaction in Sweden.

M&A Deal Summary
Date 2011-11-04
Target Cellartis AB
Sector Life Science
Buyer(s) Cellectis
Deal Type Add-on Acquisition

Target

Cellartis AB

Gothenburg,, Sweden
Cellartis recognized as a premier provider of stem cell derived products and technologies. Company to bring to the market hepatocytes and cardiomyocytes derived from pluripotent stem cells for use as drug discovery tools and is widely.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Cellectis

Paris, France
Category Company
Founded 1999
Sector Life Science
Employees203
Revenue 50M EUR (2015)
DESCRIPTION

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). Cellectis was founded in 1999 and is based in Paris, France.

DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Sweden M&A 1 of 1
Year: 2011 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-09-09 Cyto Pulse Sciences

Glen Burnie, Maryland, United States

Cyto Pulse Sciences specializing in the development, manufacture and commercialization of electroporation technology and equipment.

Buy $2M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-29 Cellectis AB

Gothenburg, Sweden

Cellectis AB is a biotechnology company focused on applications of human embryonic stem cell (HES) based products and technologies for the industry and the research community.

Sell -
Mergr

Solution for

Product

Company

Legal